Adamas Pharmaceuticals, Inc. focuses on the discovery, development, and commercialization of medicines for patients suffering from chronic neurologic disorders in the United States. The company offers GOCOVRI, an extended release capsule for the treatment of dyskinesia in patients with Parkinson's disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications. It is also developing ADS-5102 that is in Phase III clinical study to treat walking impairment in patients with multiple sclerosis and other indications; and ADS-4101, which has completed two Phase I studies for treating partial onset seizures in patients with epilepsy. In addition, the company offers Namzaric (memantine hydrochloride extended release and donepezil hydrochloride) capsules for the treatment of moderate to severe dementia of an Alzheimer's type. The company was formerly known as NeuroMolecular Pharmaceuticals, Inc. and changed its name to Adamas Pharmaceuticals, Inc. in July 2007. Adamas Pharmaceuticals, Inc. was founded in 2000 and is headquartered in Emeryville, California.

Adamas Pharmaceuticals, Inc.

Corcept Therapeutics Incorporated discovers, develops, and commercializes drugs for the treatment of severe metabolic, oncologic, and neuropsychiatric disorders in the United States. The company offers Korlym (mifepristone) tablets as a once-daily oral medication for the treatment of hyperglycemia secondary to hypercortisolism in adult patients with endogenous Cushing's syndrome, who have type 2 diabetes mellitus or glucose intolerance, and have failed surgery or are not candidates for surgery. It is developing relacorilant to treat patients with Cushing's syndrome; and nab-paclitaxel in combination with relacorilant, which has completed Phase II clinical trial to treat patients with advanced ovarian tumors, as well as for the treatment of cortisol excess. The company is also developing selective cortisol modulator to treat patients with metastatic castration-resistant prostate cancer; selective cortisol modulator for the treatment of antipsychotic-induced weight gain and other disorders; and FKBP5 gene expression assays. Corcept Therapeutics Incorporated was incorporated in 1998 and is headquartered in Menlo Park, California.

Corcept Therapeutics Incorporated

Supernus Pharmaceuticals is a biopharmaceutical company with more than 30 years of experience in developing and commercializing products that treat central nervous system (CNS) diseases.

Metric
Company Name	Adamas Pharmaceuticals, Inc.	Corcept Therapeutics Incorporated
Symbol	ADMS	CORT
MSH ID	COM:ADAMASPHARMA	COM:CORCEPT
Market	STOCKS	STOCKS
Sector	Healthcare	Healthcare
Industry	Drug Manufacturers - Specialty & Generic	Biotechnology
Country	US	US
Stage
Employee Count	138	352
Website	adamaspharma.com	corcept.com
LinkedIn
Founders

Metric
Market Cap		3.19B
Enterprise Value
Monthly Web Traffic		53.48K
Web Traffic Growth		3.98
Valuation
Raised Capital

Metric
Revenue		482.38M
Revenue (LTM)
Revenue (NTM)
Gross Profit		475.89M
EBITDA		109.64M
Operating Income		107.28M
Net Income		106.14M
EPS		1.02
Diluted EPS		0.94
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin		0.99
Operating Profit Margin		0.23
EBITDA Margin		0.23
Net Profit Margin		0.23
Return on Equity		0.24
Return on Assets		0.18
Return on Capital Employed		0.22

ADMS

COM:ADAMASPHARMA

Supernus Pharmaceuticals

Last Close

8.22

01/01 00:00

Volume Today

3.15M

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio		24.15
P/B Ratio		4.78
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio		9.13
EV Multiple		41.21

Metric
Days Sales Outstanding		39.44
Days Payables Outstanding		1.00K
Days Inventory Outstanding		435.27
Operating Cycle		476.98
Cash Conversion Cycle		-212.43
Asset Turnover		0.80

Metric
Operating Cash Flow		127.04M
Free Cash Flow		126.90M
Cash Flow to Debt		1.64K
Operating Cash Flow/Sales		0.26
Free Cash Flow Yield		0.07

Metric
Cash & Equivalents		135.55M
Accounts Receivable		-10.07M
Inventory		7.73M
Goodwill
Debt to Capitalization		0.01
Debt to Assets		0.00
Current Ratio		3.54
Quick Ratio		5.48

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue		0.10
R&D to Revenue		0.37
SG&A to Revenue